

Androgen receptor antagonists - Pipeline Insight, 2022

<https://marketpublishers.com/r/A71A0A7C1E3EEN.html>

Date: January 2022

Pages: 60

Price: US\$ 2,000.00 (Single User License)

ID: A71A0A7C1E3EEN

Abstracts

This report can be delivered to the clients within 48 Hours

DelveInsight's, "Androgen receptor antagonists - Pipeline Insight, 2022" report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Androgen receptor antagonists pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Androgen receptor antagonists Understanding

Androgen receptor antagonists: Overview

The androgen receptor (AR) pathway is emerging as a potential therapeutic target in breast cancer. AR-targeted drugs have been approved for treatment of prostate cancer; however, AR-targeted treatment for breast cancer is an area of active investigation.

Androgen receptor consists of 4 domains, an N-terminal domain, a DNA-binding domain, a hinge, and a ligand-binding domain, and functions as a nuclear transcription factor.⁹ In the absence of ligand, AR attaches to heat shock proteins and is located mainly in the cytoplasm.¹⁰ In the presence of ligand, the ligand-binding domain is unbound from heat shock protein and AR translocates into the nucleus, where the DNA-binding domain binds to androgen responsive elements in DNA and recruits additional

coactivators, corepressors, and transcriptional modulators.

The AR antagonists, which are among the therapeutic agents most commonly used to treat prostate cancer, include several categories of drugs, for example, AR antagonists and CYP17A antagonists.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Androgen receptor antagonists R&D. The therapies under development are focused on novel approaches for Androgen receptor antagonists.

Androgen receptor antagonists Emerging Drugs Chapters

This segment of the Androgen receptor antagonists report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Androgen receptor antagonists Emerging Drugs

Enzalutamide: Pfizer

Enzalutamide acts as androgen receptor antagonists. It is approved for Prostate cancer. It is currently in phase II for, breast cancer, ovarian cancer, salivary gland cancer and is being developed by Pfizer in collaboration with Astellas Pharma.

In order to promote the advancement of scientific knowledge concerning the mechanisms of action, underlying biology, and clinical effectiveness of enzalutamide in prostate cancer, the National Comprehensive Cancer Network (NCCN), Pfizer Global Medical Grants (Pfizer) and Astellas Pharma Global Development (Astellas) are collaborating.

TRC-253: Tracon Pharmaceuticals

TRC253 is a novel, orally bioavailable small molecule discovered and developed by Janssen Pharmaceutica that is a potent, high affinity competitive inhibitor of the androgen receptor (AR). TRC253 is intended to address resistance mechanisms to current AR inhibitors by specifically targeting mutations in the AR ligand binding domain. TRC253 also potently inhibits signalling through the wild type AR. These susceptible AR mutations have been identified using circulating tumor DNA assays, potentially allowing for selected patient biomarker-directed therapy. It is being developed by Traccon Pharmaceuticals in collaboration with Janssen Pharmaceutica.

It is currently in phase II stage of development for the treatment of Prostate cancer.

Further product details are provided in the report.....

Androgen receptor antagonists: Therapeutic Assessment

This segment of the report provides insights about the different Androgen receptor antagonists drugs segregated based on following parameters that define the scope of the report, such as:

Major Players working on Androgen receptor antagonists

There are approx. 20+ key companies which are developing the Androgen receptor antagonists. The companies which have their Androgen receptor antagonists drug candidates in the most advanced stage, i.e. Phase II include, Pfizer.

Phases

DelveInsight's report covers around 20+ products under different phases of clinical development like

Late-stage products (Phase III)

Mid-stage products (Phase II)

Early-stage products (Phase I/II and Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Androgen receptor antagonists pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Infusion

Intradermal

Intramuscular

Intranasal

Intravaginal

Oral

Parenteral

Subcutaneous

Topical

Molecule Type

Products have been categorized under various Molecule types such as

Vaccines

Monoclonal Antibody

Peptides

Polymer

Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Androgen receptor antagonists: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Androgen receptor antagonists therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Androgen receptor antagonists drugs.

Androgen receptor antagonists Report Insights

Androgen receptor antagonists Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

Androgen receptor antagonists Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:

How many companies are developing Androgen receptor antagonists drugs?

How many Androgen receptor antagonists drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for Androgen receptor antagonists?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Androgen receptor antagonists therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Androgen receptor antagonists and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

Tracon Pharmaceuticals

MAIA Biotechnology

Xennials Therapeutics

Pfizer

Chia Tai Tianqing Pharmaceutical Group

ESSA Pharma

Novan

Key Products

TRC-253

MJC13

XNTR-955

XNTR-934

XNTR-936

Enzalutamide

TQB3720

EPI-7386

SB-206

Contents

Introduction

Executive Summary

Androgen receptor antagonists: Overview

Structure

Mechanism of Action

Pipeline Therapeutics

Comparative Analysis

Therapeutic Assessment

Assessment by Product Type

Assessment by Stage and Product Type

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

Androgen receptor antagonists– DelveInsight's Analytical Perspective

In-depth Commercial Assessment

Androgen receptor antagonists companies' collaborations, Licensing, Acquisition

-Deal Value Trends

Androgen receptor antagonists Collaboration Deals

Company-Company Collaborations (Licensing / Partnering) Analysis

Company-University Collaborations (Licensing / Partnering) Analysis

Late Stage Products (Phase III)

Comparative Analysis

Drug name: Company Name

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Mid Stage Products (Phase II)

Comparative Analysis

Enzalutamide: Pfizer

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Early Stage Products (Phase I)

Comparative Analysis

TQB3720: Chia Tai Tianqing Pharmaceutical Group

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Preclinical and Discovery Stage Products

Comparative Analysis

XNTR-955: Xennials Therapeutics

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Inactive Products

Comparative Analysis

Androgen receptor antagonists Key Companies

Androgen receptor antagonists Key Products

Androgen receptor antagonists- Unmet Needs

Androgen receptor antagonists- Market Drivers and Barriers

Androgen receptor antagonists- Future Perspectives and Conclusion

Androgen receptor antagonists Analyst Views

Androgen receptor antagonists Key Companies

Appendix

List Of Tables

LIST OF TABLES

Table 1 Total Products for Androgen receptor antagonists

Table 2 Late Stage Products

Table 3 Mid Stage Products

Table 4 Early Stage Products

Table 5 Pre-clinical & Discovery Stage Products

Table 6 Assessment by Product Type

Table 7 Assessment by Stage and Product Type

Table 8 Assessment by Route of Administration

Table 9 Assessment by Stage and Route of Administration

Table 10 Assessment by Molecule Type

Table 11 Assessment by Stage and Molecule Type

Table 12 Inactive Products

List Of Figures

LIST OF FIGURES

Figure 1 Total Products for Androgen receptor antagonists

Figure 2 Late Stage Products

Figure 3 Mid Stage Products

Figure 4 Early Stage Products

Figure 5 Preclinical and Discovery Stage Products

Figure 6 Assessment by Product Type

Figure 7 Assessment by Stage and Product Type

Figure 8 Assessment by Route of Administration

Figure 9 Assessment by Stage and Route of Administration

Figure 10 Assessment by Molecule Type

Figure 11 Assessment by Stage and Molecule Type

Figure 12 Inactive Products

I would like to order

Product name: Androgen receptor antagonists - Pipeline Insight, 2022

Product link: <https://marketpublishers.com/r/A71A0A7C1E3EEN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/A71A0A7C1E3EEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970